Skip to Content
CN
EN
Products
Applications
Services
Resources
Support
Analytical Chemistry
Cell Culture & Analysis
Chemistry & Biochemicals
Clinical & Diagnostics
Filtration
Greener Alternative Products
Industrial Microbiology
Lab Automation
Labware
Materials Science
Molecular Biology & Functional Genomics
mAbs Development & Manufacturing
mRNA Development & Manufacturing
Pharma & Biopharma Manufacturing
Protein Biology
Water Purification
Analytical Chemistry
Cell Culture & Analysis
Chemistry & Synthesis
Clinical & Diagnostics
Environmental & Cannabis Testing
Food & Beverage Testing & Manufacturing
Genomics
Materials Science & Engineering
Microbiological Testing
mAbs Development & Manufacturing
mRNA Development & Manufacturing
Pharma & Biopharma Manufacturing
Protein Biology
Research & Disease Areas
Water Purification
Contract Manufacturing
Contract Testing
Custom Products
Digital Solutions for Life Science
IVD Development & Manufacturing
Product Services
Support
Documents
Learning Center
New
User Guide for Millipore Website Consolidation
Web Training
Ordering Information
Customer Support
After-Sales Support
Technical Support
Process Solution Support
Contact Us
Get Site Smart
FAQ
Quality & Regulatory
Calculators & Apps
Webinars
Home
Search Results
New oral hypoglycaemics fail to show cardiovascular benefits.
New oral hypoglycaemics fail to show cardiovascular benefits.
BMJ (Clinical research ed.) (2013-09-10)
Deborah Cohen
PMID
24014343
MATERIALS
Product Number
Brand
Product Description
100277
Sigma-Aldrich
Adamantane, ≥99%
Pricing
V900439
Sigma-Aldrich
Uracil, Vetec
™
, reagent grade, 98%
Pricing
U1128
Sigma-Aldrich
Uracil, BioReagent, suitable for cell culture
Pricing
U0750
Sigma-Aldrich
Uracil, ≥99.0%
Pricing
